Effect of Various Treatment Modalities on Dendritic Vial Ulcer
1 other identifier
observational
40
1 country
1
Brief Summary
Eye infection is a prevalent problem in primary care and remains a crucial healthcare concern. According to the American Academy of Ophthalmology (AAO), herpes simplex virus (HSV) keratitis (HSK) is the leading cause of infectious blindness worldwide . HSK is defined as a corneal inflammatory condition caused by the HSV infection . The global incidence of herpetic keratitis is estimated at 1.5 million per year, resulting in 40,000 new cases of severe visual impairment associated with corneal scarring and opacification . HSV type I (HSV-1) is by far the most predominant causative pathogen of eye infections\]. HSV-1 is also known for causing orolabial herpes, HSV folliculitis, herpes gladiatorum, herpetic whitlow, and eczema herpeticum . HSV can be transferred to the eye by touching an active lesion and then the eye. The National Health and Nutrition Evaluation revealed a seroprevalence of HSV-1 in 53.9% of 14-49 year olds, and 90% of adults 50 years or older , indicating that the majority of the population has been exposed to this virus thus are at risk of developing HSK. In this study we evaluate the efficacy of different treatment modalities on viral keratitis HSK.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for all trials
Started Mar 2022
Shorter than P25 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
March 18, 2022
CompletedFirst Submitted
Initial submission to the registry
March 26, 2022
CompletedFirst Posted
Study publicly available on registry
April 6, 2022
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 28, 2022
CompletedStudy Completion
Last participant's last visit for all outcomes
July 20, 2022
CompletedApril 6, 2022
April 1, 2022
3 months
March 26, 2022
April 4, 2022
Conditions
Outcome Measures
Primary Outcomes (1)
healing of the epithelium
the epithelial healing assessed with flourescin stain and measured by slit lamp scale in millimetres and compared with pre treatment epithelial defect
10 days follow up
Study Arms (4)
group 1'
patients with viral ulcers will receive antiviral medication with antibiotics
group 2
patients with viral ulcers will receive antiviral medication, tear substitutes with antibiotics
group 3
patients with viral ulcers will receive antiviral medication, weak steroids(at the same time) with antibiotics
group 4
patients with viral ulcers will receive antiviral medication with antibiotics followed by weak steroid after epithelial healing
Interventions
Eligibility Criteria
patients suffering from epithelial viral keratitis
You may qualify if:
- patients with epithelial viral ulcers
You may not qualify if:
- patients with stromal keratitis patients with corneal opacity
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Sohag Universitylead
Study Sites (1)
Sohag University
Sohag, 82524, Egypt
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- CASE CONTROL
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- principal investigator
Study Record Dates
First Submitted
March 26, 2022
First Posted
April 6, 2022
Study Start
March 18, 2022
Primary Completion
June 28, 2022
Study Completion
July 20, 2022
Last Updated
April 6, 2022
Record last verified: 2022-04
Data Sharing
- IPD Sharing
- Will share
- Shared Documents
- STUDY PROTOCOL, SAP, ICF, CSR, ANALYTIC CODE